FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress

ENGLEWOOD, Colo., Sept. 21, 2020 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") announces the receipt of an Investigational New Drug ("IND") from the U.S. Food and Drug Administration ("FDA"), allowing the Company to proceed......
. .
Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Monday, 21 September

Share |